Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

This publication has 87 references indexed in Scilit:

• A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
  Breast Cancer Research and Treatment, 2013
• A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
  Breast Cancer Research and Treatment, 2012
• A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
  Breast Cancer Research and Treatment, 2012
• Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
  New England Journal of Medicine, 2012
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
  The Lancet Oncology, 2012
• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
  Oncogene, 2011
• Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
  Cancer Cell, 2009
• Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
  Nature, 2007
• Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
  JAMA, 2006
• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
  New England Journal of Medicine, 2005